Vitamin K2.

Vitamin D3 raises calcium absorption and drives production of osteocalcin, one of the proteins that vitamin K2 has to carboxylate before it can work. K2 then activates that osteocalcin and matrix Gla protein, so the calcium D3 brings in gets bound into bone rather than deposited in soft tissue.

Vitamin K2 carboxylates osteocalcin and matrix Gla protein, the proteins that bind calcium into the bone matrix and hold it out of soft tissue. K2 adds no calcium of its own; it governs where supplemented calcium ends up.

Magnesium is a required cofactor for the enzymes that turn vitamin D into its active form, and active vitamin D is what teams with K2 to route calcium into bone. Magnesium is also part of bone mineral itself, so it supports the same normal mineralization the D3 and K2 pairing feeds, though its connection to K2 runs through vitamin D rather than being direct.

Menaquinones run the same vitamin K cycle as phylloquinone, with the epoxide reductase regenerating the reduced quinol after each carboxylation. Total vitamin K activity is the sum of the two families.

Phylloquinone is cleared quickly and is used mainly in liver, while menaquinones persist in circulation and reach bone and vessel wall. Together they cover hepatic and extrahepatic carboxylation.

MK-7 carries a longer isoprenoid side chain than MK-4, binds lipoproteins more tightly and stays in circulation for days rather than hours. It is the menaquinone that delivers steady extrahepatic carboxylation.

MK-4 and coenzyme Q10 are both built from the same mevalonate-derived isoprenoid units, and the enzyme UBIAD1 handles the prenylation step for menaquinone-4. Anything that limits that shared pathway limits both quinones together.

High alpha-tocopherol intakes interfere with the vitamin K cycle and with menaquinone absorption, lowering carboxylation of vitamin K-dependent proteins and adding to effects on normal clotting. Formulas holding both keep the tocopherol dose moderate.

Menaquinones need bile salts and dietary fat to form the micelles that carry them into the enterocyte, so an oil carrier raises the absorbed fraction. Oil bases are standard in K2 softgels for this reason.

Menaquinones and retinol are both absorbed in mixed micelles and exported in chylomicrons, so their uptake depends on the same dietary fat and bile. At the transcriptional level, retinoic acid receptors heterodimerise with the vitamin D receptor and influence osteocalcin expression, and osteocalcin is the protein vitamin K carboxylates. This is established signalling biology rather than a combination trial, and high retinol intake carries its own upper-limit considerations.

Vitamin K is the cofactor for gamma-carboxylation of clotting factors II, VII, IX and X, so it supports normal coagulation capacity. Nattokinase is a fibrinolytic enzyme from the same fermentation that acts on the clot-dissolving side. The two are frequently sold from the same natto source while pulling in opposite directions on the same system, which is a formulation fact worth stating rather than a benefit.

Bone is a mineralised collagen scaffold. Vitamin C is needed to hydroxylate proline and lysine residues so that collagen triple helices form and cross-link, which is textbook enzymology. Vitamin K acts later, carboxylating osteocalcin and matrix Gla protein so they can bind calcium at that scaffold. The two occupy different steps of normal bone matrix handling.

Boron affects urinary calcium and magnesium excretion and circulating steroid hormone concentrations in controlled feeding work, placing it in the same mineral-handling territory as the vitamin K dependent Gla proteins. The overlap is at the level of bone mineral economy rather than a shared enzyme. No combination study in the candidate list tested the pair.

Dietary silicon has been linked to bone mineral density in cohort analyses, which is an association and not a demonstrated cause, and animal work points at collagen matrix formation. Vitamin K acts on the Gla proteins that bind mineral to that matrix. The pairing is a matrix-plus-mineral-binding rationale at early confidence.

Strontium is a calcium analogue that incorporates into bone mineral and also interferes with densitometry readings because of its higher atomic number, so density measurements taken during use overstate mineral content. Vitamin K acts on the protein side of mineralisation, not the ion. The pairing is coherent chemically, and the measurement caveat is the part worth stating.

Alkaline phosphatase is a zinc metalloenzyme that hydrolyses pyrophosphate, an inhibitor of mineral deposition, and its activity is a routine marker of osteoblast function. Vitamin K carboxylates osteocalcin secreted by those same osteoblasts. Zinc supplies the cofactor, vitamin K enables the calcium-binding protein, and the two steps are distinct.

Bone is roughly a third organic matrix, predominantly type I collagen. Collagen peptides supply glycine, proline and hydroxyproline plus di- and tripeptides that reach circulation intact. Vitamin K acts on osteocalcin and matrix Gla protein rather than on collagen itself, so the two address different halves of bone tissue. No combination trial is in the candidate set.

Menaquinones MK-5 through MK-13 are produced by gut bacteria including Bacteroides and Escherichia species, and appreciable amounts are found in the colon. How much of that pool is absorbed from the colon is limited and not well quantified, so this is a real biosynthetic route with an uncertain contribution. It is a mechanism note, not a reason to expect a supplement-scale effect from cultures alone.

Vitamin K is fat soluble and its uptake rises when taken with a fat-containing meal, which is established absorption physiology. A marine oil supplies that fat and shares the chylomicron route, where MK-7 in particular circulates bound to low density lipoprotein. The pairing is about delivery; the size of the absorption difference depends on the meal and the format.

Lecithin lowers interfacial tension and reduces oil droplet size, increasing the surface area pancreatic lipase and bile salts can act on. Fat-soluble vitamin formats routinely use it for that reason. This is formulation physiology and does not by itself predict a clinical difference.

The vitamin K cycle depends on reduction of the quinone to hydroquinone, work done by NAD(P)H-dependent and flavin-linked reductases including NQO1 alongside vitamin K epoxide reductase. Riboflavin supplies the flavin cofactors those reductases use. The link is at cofactor supply for the recycling step, and it is early rather than measured.

NQO1 uses NADH or NADPH to reduce vitamin K quinone to the hydroquinone that gamma-glutamyl carboxylase requires, which is the warfarin-insensitive arm of the vitamin K cycle. Pyridine nucleotide availability is therefore an input to that step. This is established enzymology; nothing here says a nicotinamide precursor supplement changes carboxylation in people.